CoMiSS, the “Cow’s Milk related Symptom Score”,  is a valuable resource for healthcare professionals, parents, and carers alike, offering an easy-to-use awareness tool that supports the recognition of cow’s milk-related symptoms in infants and young children. 2024 marks the 10th anniversary of CoMiSS, prompting us to look back at the decade of science and clinical practice behind the tool. The podcast reflects on the tool’s inception, its impact on aiding earlier diagnosis, and its role in evaluating therapeutic interventions for managing symptoms of cow’s milk allergy (CMA).

This podcast episode dives into the screening and management of Duchenne muscular dystrophy, as well as diversity in genetic databases, and treating neuromuscular disorders. Jonathan is joined by Madhuri Hegde, Senior Vice-President & Chief Scientific Officer at Revvity, Inc., to talk about innovation in genomic testing. Use the following timestamps to navigate our episode!   (00:00)-Introduction  (03:54)-Entering into genomic technologies (05:13)-Duchenne muscular dystrophy (10:47)-Revvity and genome sequencing (13:13)-Ultrarapid genomic testing (urWGS) (15:18)-LANTERN project (17:42)-Lack of diversity in genetic databases (20:06)-New developments in genetics (22:19)-COVID-19 testing laboratories (27:27)-Madhuri’s wishes for healthcare

Jonathan is joined by Joshua Makower, Director and Co-Founder of the Stanford Byers Center for Biodesign, Stanford University, California, USA. The pair navigate fascinating themes, from Makower’s passion for music and his band, Still Trust, to innovative strategies for controlling rising healthcare costs through innovation. Makower offers perspectives on AI in healthcare, and the associated challenges with regulating these new technologies. Use the following timestamps to navigate the topics discussed in this episode: (00:00)-Introduction  (03:05)-A passion for music  (06:11)-From the Massachusetts Institute of Technology (MIT) to medical school  (08:50)-The Biodesign process  (19:37)-Driving technology from mind to marketplace  (23:25)-Doctors engaging with industry  (27:52)-The ExploraMed incubator  (31:07)-Josh’s current work  (34:27)-The importance of failure  (36:16)-Perspectives on artificial intelligence in healthcare  (39:05)-Healthcare innovation horizons  (40:37)-Medical technology regulation  (46:00)-Josh’s three wishes for the future of healthcare

In this bonus episode of the EMJ podcast, host Sue Saville, a medical correspondent, discusses the latest advancements in access and hemostasis for coronary and other procedures via the distal radial route. Joined by Pavan Najran, clinical lead for interventional radiology and Consultant Clinical and Interventional Radiologist, The Christie Hospital NHS Foundation Trust, Manchester, UK, they further explore the benefits of the distal radial method, emphasizing reduced vascular complications, improved patient comfort, and shorter haemostasis time. Najran highlights the ergonomic advantages, dispels misconceptions, and shares insights from trials and personal experience, showcasing the potential for distal radial access to become the preferred approach. Pavan Najran, is a clinical lead for interventional radiology and Consultant Clinical and Interventional Radiologist, The Christie Hospital NHS Foundation Trust, Manchester, UK. The publication of this podcast was funded by Merit Medical. Dr Najran is a consultant to Merit Medicall. The suggestions and other information, which may include both Merit and third-party products, are for the practitioner’s convenience and for general information purposes only. This information does not constitute medical or legal advice, nor is it meant to endorse or guarantee the suitability of any of the referenced products or methods for any specific patient or procedure. Before using, refer to the Instructions for Use (IFU) for indications, contraindications, warnings, precautions, and directions for use.

This podcast explores the fascinating world of artificial intelligence and advances on the horizon in oncology. Jonathan and Sofia Merajver, Michigan Medicine, Ann Arbor, USA, discuss vaccine hesitancy, the promise of artificial intelligence in generating large datasets, and non-small cell lung cancer, before concluding with her three wishes for healthcare.   Use the following tiestamps tot navigate the episode!  (00:00)-Introduction (00:46)-Breast cancer vaccine hesitancy (07:38)-Advances on the horizon to prevent, protect, and treat malignancies (09:30)-Hospitals in areas of conflict (12:20)-Artificial intelligence (17:28)-Non-small cell lung cancer (23:10)-Sofia’s three wishes for healthcare

This podcast explores the genetic determinants and mechanisms of breast and ovarian cancer. Jonathan and Sofia Merajver, Michigan Medicine, Ann Arbor, USA, discuss brain metastases, the severity of inflammatory breast cancer, and the movement of cancers through tissue. Use the following timestamps to navigate this episode! (00:00)-Introduction (02:27)-Sofia’s journey into medicine (04:10)-Personal stakes (05:09)-Not being your doctor (06:58)-Genes in inflammatory breast cancer (10:58)-RHO proteins (12:52)-Brain metastasis (17:33)-Crossing the blood–brain barrier (22:11)-Aggressive phenotypes of breast cancer (24:18)-Chemoprevention in breast cancer

This podcast explores the mOm Incubator, the importance of collaboration with healthcare professionals when designing medical devices, and the environmental impact of healthcare. Jonathan is joined by James Roberts, co-founder and CEO of mOm Incubators Ltd., a MedTech start-up on a mission to provide global access to high-quality healthcare. The pair discuss how the mOm incubator compares to traditional incubators, and the problems it solves.   Use the following timestamps to navigate this episode! (00:00)-Introduction (02:11)-Sparking interest in medical innovation (04:11)-Navigating a medical device start-up (07:03)-Unveiling the mOm incubator (10:19)-The value of input from HCPs in device development (13:04)-Delivering a simple yet low-risk device (16:14)-Supplying mOm incubators to Ukraine (20:16)-Considering the environmental impacts of medical devices (23:30)-James’ proudest achievements (26:58)-Looking to the future (28:48)-Transport for London’s map of engineering icons (31:09)-Three wishes for the future of healthcare

In this bonus episode of the EMJ podcast, Dr. Douglas Bradley is joining our host Dr Hannah Moir to discuss the recent outcomes from the ADVENT-HF randomised clinical trial. The discussion revolves around the relationship between heart failure and co-existing obstructive and/or central sleep apnoea. Dr Bradley considers the use of adaptive servo-ventilation (ASV), a non-invasive positive airway therapy, and provides insights on the trial outcomes. He also delves into the mechanism of action underlying ASV and discusses future developments in the sleep and cardiovascular space.   This podcast has been funded by Philips.

In this final episode of the series, the discussion focuses on the role of therapeutic drug monitoring and current practices, as well as how treatment decisions are made for patients refractory to anti-TNFs. The guests conclude by discussing the future of anti-TNFs and identifying the remaining gaps in the care of patients with inflammatory bowel disease. This podcast series has been supported by Viatris, who were not involved in the creation of this content.

In this penultimate episode of the series on anti-TNFs for inflammatory bowel disease, our expert gastroenterologists discuss treatment options for difficult-to-treat Crohn’s disease and ulcerative colitis, including recent views and decision-making. This podcast series has been supported by Viatris, who were not involved in the creation of this content.

Expanding the discussion of the use of anti-TNF biosimilars, in this episode, our expert panel provides insights on switching and the handling of adalimumab biosimilars. This podcast series has been supported by Viatris, who were not involved in the creation of this content.

In this episode, our expert gastroenterologists consider the importance of anti-TNF biosimilars as a treatment option for inflammatory bowel disease and the corresponding guideline recommendations. This podcast series has been supported by Viatris, who were not involved in the creation of this content.

In this episode, our experts discuss the use of combination therapy involving anti-TNFs and immunomodulators, with a focus on the synergy and immunogenic effects, clinical trial outcomes, and the conversations that need to be had with patients. This podcast series has been supported by Viatris, who were not involved in the creation of this content.

Our expert gastroenterologists continue their discussion of the side effects and risks of anti-TNFs, including infection, vaccine immunogenicity, and tuberculosis (TB) risk, as well as monitoring approaches. This podcast series has been supported by Viatris, who were not involved in the creation of this content.

Our gastroenterology experts consider the patient's underlying comorbidities when making treatment decisions regarding anti-TNFs. They also evaluate the safety profile and risks, particularly for elderly patients This podcast series has been supported by Viatris, who were not involved in the creation of this content.

In this episode, our experts discuss the recommended clinical anti-TNF treatments for inflammatory bowel disease in Europe and the USA and the patient factors that should be considered in patient decision-making. This podcast series has been supported by Viatris, who were not involved in the creation of this content.

In this episode, our expert gastroenterologists provide a summary of the current ECCO and AGA recommendations for the use of anti-TNFs and insights on potential updates. This podcast series has been supported by Viatris, who were not involved in the creation of this content.

This introductory episode provides an introduction to the role anti-TNF therapies play in the management of inflammatory bowel disease, ulcerative colitis and Crohn’s disease This podcast series has been supported by Viatris, who were not involved in the creation of this content.

In this week’s episode, Jonathan and George Bakris, Comprehensive Hypertension Center, University of Chicago, Illinois, USA, chat about hypertension and renal denervation. Use the following timestamps to navigate the content in this episode: (00:00)-Introduction (00:40)-Renal denervation Vs drugs in development for resistant hypertension (06:06)-Get with the guidelines (11:05)-Disparities in kidney disease incidence (16:25)-Novel diabetes drugs (19:42)-Remaining challenges in treating hypertension (26:30)-Three wishes for healthcare

This podcast is supported by Medtronic. This podcast episode, moderated by George Cooper, provides an exploration of the latest European Society of Hypertension (ESH) guidance on the use of renal denervation in uncontrolled hypertension management. Atul Pathak, Princess Grace Hospital, Monaco, joins EMJ to offer key insights on renal denervation.